|
|
 |
International Clinical Trials in Endocrinology
Argentina
Australia
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Adelaide; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Sydney; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
Adelaide; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
Canberra; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
St. Leonards; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Adelaide; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Sydney; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Adelaide; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Heidelberg; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Sydney; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Heidelberg; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Sydney; Research Site:
- Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Adelaide; Research Site:
- Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Sydney; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Melbourne; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
St. Leonards; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Sydney; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Adelaide; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Ballarat; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Brisbane; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Canberra; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Liverpool; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
St. Leonards; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Sydney; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Adelaide; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Heidelberg; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Melbourne; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
St. Leonards; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Sydney; Research Site:
Austria
Belgium
Brazil
Bulgaria
- Diabetes Mellitus, Type 2: A Comparative Study of Aleglitazar and Actos�® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
Stara Zagora; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Dimitrovgrad; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Pleven; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Ruse; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Sofia; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Varna; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Ruse; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Sofia; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
Dimitrovgrad; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
Pleven; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
Ruse; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
Sofia; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Dimitrovgrad; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Pleven; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Ruse; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Sofia; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Gabrovo; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Pleven; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Plovdiv; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Sofia; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Varna; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Vratza; Research Site:
Canada
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Halifax, NS; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
London, ON; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Toronto, ON; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Winnipeg, MB; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
London, ON; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Montreal, QC; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Sherbrooke, QC; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Vancouver, BC; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
London, ON; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Montreal, QC; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Vancouver, BC; Research Site:
- Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Calgary, AB; Research Site:
- Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Kelowna, BC; Research Site:
- Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Surrey, BC; Research Site:
- Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Vancouver, BC; Research Site:
- Ovarian Cancer: National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Edmonton; Cross Cancer Institute
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Edmonton, AB; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Toronto, ON; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Edmonton, AB; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Montreal, QC; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Ottawa, ON; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Quebec City, QC; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Toronto, ON; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Vancouver, BC; Research Site:
China
Costa Rica
Croatia
Czech Republic
Denmark
Estonia
Finland
France
Germany
- Diabetes Mellitus, Type 1: Starting Basal Rate Profiles Used in Continuous Subcutaneous Insulin Infusion.
Ulm; Research Site:
- Diabetes Mellitus, Type 2: A Drug-Drug Interaction Study of GK Activator (2) and Ethanol in Patients With Type 2 Diabetes.
München; Research Site:
- Diabetes Mellitus, Type 2: A Multiple Ascending Dose Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Glimepiride.
Berlin; Research Site:
- Diabetes Mellitus, Type 2: A Multiple Ascending Dose Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Glimepiride.
Mainz; Research Site:
- Diabetes Mellitus, Type 2: A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.
Berlin; Research Site:
- Diabetes Mellitus, Type 2: A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.
Neuss; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Bad Lauterberg; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Berlin; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Görlitz; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Hannover; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Mainz; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Neuss; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Nürnberg; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Bad Lauterberg; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Berlin; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Dresden; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Görlitz; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Mainz; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Neuss; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Bammental; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Berlin; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Essen; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Giessen; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Görlitz; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Hamburg; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Kuenzing; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Mannheim; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Nürnberg; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Tann; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Effect of GK Activator (2) on QT Interval in Patients With Type 2 Diabetes Mellitus.
Neuss; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Bammental; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Berlin; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Giessen; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Görlitz; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Hamburg; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Kuenzing; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Nürnberg; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Tann; Research Site:
- Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Berlin; Research Site:
- Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
München; Research Site:
- Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Neuss; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Bochum; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Dresden; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Esslingen; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Frankfurt Am Main; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Köln; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Magdeburg; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Berlin; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Bochum; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Bonn; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Esslingen; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Frankfurt Am Main; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Halle; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Hamburg; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Hamm; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Kaiserslautern; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Leipzig; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Marburg; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Münchengladbach; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Saarbruecken; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Trier; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Berlin; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Bochum; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Bonn; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Hamburg; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Heidelberg; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Leipzig; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Magdeburg; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Mainz; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
München; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Münchengladbach; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Trier; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Ulm; Research Site:
- Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
Bochum; Research Site:
- Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
Esslingen; Research Site:
- Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
Freiburg; Research Site:
- Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
Heidelberg; Research Site:
- Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
Mainz; Research Site:
- Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
Mannheim; Research Site:
- Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
München; Research Site:
- Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
Regensburg; Research Site:
- Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
Tübingen; Research Site:
- Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
Ulm; Research Site:
Greece
Guatemala
Hungary
India
Israel
Italy
- Diabetes Mellitus, Type 1: A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine.
Bergamo; Research Site:
- Diabetes Mellitus, Type 1: A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine.
Brescia; Research Site:
- Diabetes Mellitus, Type 1: A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine.
Padova; Research Site:
- Diabetes Mellitus, Type 1: A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine.
Pisa; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Bologna; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Genova; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Napoli; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Olbia; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Perugia; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Pordenone; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Roma; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Siena; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Torino; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Ancona; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Firenze; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Napoli; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Udine; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Ancona; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Asti; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Bari; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Bassano del Grappa; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Bergamo; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Catania; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Catanzaro; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Foggia; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Forli; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Genova; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Messina; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Milano; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Monfalcone; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Olbia; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Padova; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Palermo; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Perugia; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Pescara; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Prato; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Quartu S. Elena-Cagliari; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Roma; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
S.Benedetto del Tronto (AP); Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Salerno; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Siena; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Terni; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Torino; Research Site:
- Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
Udine; Research Site:
- Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Milano; Research Site:
- Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Modena; Research Site:
- Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Parma; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Bologna; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Ferrara; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Firenze; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Udine; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Chieti; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Firenze; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Napoli; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Orbassano; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Pordenone; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
San Giovanni Rotondo; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Udine; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Bologna; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Chieti; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Genova; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Napoli; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Orbassano; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Parma; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
San Giovanni Rotondo; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
Bari; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
Bologna; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
Catania; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
Ferrara; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
Napoli; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
Pavia; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
Perugia; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
Pisa; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
Pordenone; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
Roma; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
Verona; Research Site:
Latvia
Lithuania
Malaysia
Mexico
- Diabetes Mellitus, Type 2: A Comparative Study of Aleglitazar and Actos�® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
Culiacan; Research Site:
- Diabetes Mellitus, Type 2: A Comparative Study of Aleglitazar and Actos�® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
Guadalajara; Research Site:
- Diabetes Mellitus, Type 2: A Comparative Study of Aleglitazar and Actos�® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
Metepec; Research Site:
- Diabetes Mellitus, Type 2: A Comparative Study of Aleglitazar and Actos�® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
Mexico City; Research Site:
- Diabetes Mellitus, Type 2: A Comparative Study of Aleglitazar and Actos�® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
Monterrey; Research Site:
- Diabetes Mellitus, Type 2: A Comparative Study of Aleglitazar and Actos�® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
San Luis Potosi; Research Site:
- Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
Chihuahua; Research Site:
- Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
Hermosillo; Research Site:
- Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
Metepec; Research Site:
- Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
Mexico City; Research Site:
- Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
Monterrey; Research Site:
- Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
Tlalpan; Research Site:
- Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
Zapopan; Research Site:
- Diabetes Mellitus, Type 2: A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
Chihuahua; Research Site:
- Diabetes Mellitus, Type 2: A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
Guadalajara; Research Site:
- Diabetes Mellitus, Type 2: A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
Pachuca; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Guadalajara; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Mexico City; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Monterrey; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Pachuca; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Aguascalientes; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Chihuahua; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Cuernavaca; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Durango; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Guadalajara; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Mexico City; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Monterrey; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Pachuca; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
Aguascalientes; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
Chihuahua; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
Guadalajara; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
Mexico City; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
Pachuca; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
Tampico; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Chihuahua; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Guadalajara; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Mexico City; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Monterrey; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Pachuca; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
Chihuahua; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
Cuernavaca; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
Durango; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
Mexico City; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Chihuahua; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Cuernavaca; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Durango; Research Site:
- Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Mexico City; Research Site:
- Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Chihuahua; Research Site:
- Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Culiacan; Research Site:
- Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Monterrey; Research Site:
- Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Tampico; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Mexico City; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Mexico City; Research Site:
- Pancreatic Cancer: A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Morelia; Research Site:
- Pancreatic Cancer: A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Tijuana; Research Site:
Netherlands
New Zealand
Peru
Poland
Romania
- Diabetes Mellitus, Type 2: A Comparative Study of Aleglitazar and Actos�® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
Baia Mare; Research Site:
- Diabetes Mellitus, Type 2: A Comparative Study of Aleglitazar and Actos�® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
Bucuresti; Research Site:
- Diabetes Mellitus, Type 2: A Comparative Study of Aleglitazar and Actos�® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
Oradea; Research Site:
- Diabetes Mellitus, Type 2: A Comparative Study of Aleglitazar and Actos�® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
Ploiesti; Research Site:
- Diabetes Mellitus, Type 2: A Comparative Study of Aleglitazar and Actos�® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
Targoviste; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Brasov; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Bucharest; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Cluj-Napoca; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Jud Covasna; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Mures; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Ploiesti; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Satu Mare; Research Site:
- Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Sibiu; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Brasov; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Bucharest; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Cluj-Napoca; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Galati; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Ploiesti; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Bucharest; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Cluj-Napoca; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Ploiesti; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Tirgu-Mures; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Bucharest; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Cluj-Napoca; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Craiova (Dolj County); Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Iasi; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Cluj-Napoca; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Sibiu; Research Site:
Russian Federation
- Diabetes Mellitus, Type 2: A Comparative Study of Aleglitazar and Actos�® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
Moscow; Research Site:
- Diabetes Mellitus, Type 2: A Comparative Study of Aleglitazar and Actos�® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
Saratov; Research Site:
- Diabetes Mellitus, Type 2: A Comparative Study of Aleglitazar and Actos�® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
St Petersburg; Research Site:
- Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
Moscow; Research Site:
- Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
Saratov; Research Site:
- Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
St Petersburg; Research Site:
- Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
Tumen; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Moscow; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
Saratov; Research Site:
- Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
St Petersburg; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
Moscow; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
Saratov; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
St Petersburg; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
Yaroslavl; Research Site:
- Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Kazan; Research Site:
- Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Moscow; Research Site:
- Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
St Petersburg; Research Site:
- Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Tomsk; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Irkutsk; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Kazan; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Krasnodar; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Moscow; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
St Petersburg; Research Site:
Serbia and Montenegro
Singapore
Slovakia
Slovenia
South Africa
Spain
- Diabetes Mellitus, Type 2: A Multiple Ascending Dose Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Glimepiride.
Alzira; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
Alzira; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
Bacarot Alicant; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
Badalona; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
Barcelona; Research Site:
- Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
Ferrol; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Alzira; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Bacarot Alicant; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Baracaldo; Research Site:
- Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Barcelona; Research Site:
- Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Barcelona; Research Site:
- Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Madrid; Research Site:
- Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Valencia; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Girona; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Madrid; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Alicante; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Barcelona; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Elche; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Madrid; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Santander; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Valencia; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival
Alcorcon; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival
Alcoy; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival
Barcelona; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival
Córdoba; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival
El Palmar Murcia; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival
Elche; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival
Girona; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival
Granada; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival
Guadalajara; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival
Jaen; Research Site:
- Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival
La Coruna; Research Site: | |
